JP2024529119A5 - - Google Patents

Info

Publication number
JP2024529119A5
JP2024529119A5 JP2024508417A JP2024508417A JP2024529119A5 JP 2024529119 A5 JP2024529119 A5 JP 2024529119A5 JP 2024508417 A JP2024508417 A JP 2024508417A JP 2024508417 A JP2024508417 A JP 2024508417A JP 2024529119 A5 JP2024529119 A5 JP 2024529119A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
polypeptide
polypeptide chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024508417A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529119A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/111717 external-priority patent/WO2023016516A1/zh
Publication of JP2024529119A publication Critical patent/JP2024529119A/ja
Publication of JP2024529119A5 publication Critical patent/JP2024529119A5/ja
Pending legal-status Critical Current

Links

JP2024508417A 2021-08-13 2022-08-11 抗vegfaとvegfc二重特異性抗体およびその使用 Pending JP2024529119A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110932078 2021-08-13
CN202110932078.7 2021-08-13
PCT/CN2022/111717 WO2023016516A1 (zh) 2021-08-13 2022-08-11 抗vegf a和vegf c双特异性抗体及其用途

Publications (2)

Publication Number Publication Date
JP2024529119A JP2024529119A (ja) 2024-08-01
JP2024529119A5 true JP2024529119A5 (cg-RX-API-DMAC7.html) 2025-08-15

Family

ID=85200580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508417A Pending JP2024529119A (ja) 2021-08-13 2022-08-11 抗vegfaとvegfc二重特異性抗体およびその使用

Country Status (7)

Country Link
US (1) US20250002570A1 (cg-RX-API-DMAC7.html)
EP (1) EP4386004A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024529119A (cg-RX-API-DMAC7.html)
CN (1) CN118043350A (cg-RX-API-DMAC7.html)
AU (1) AU2022327397B2 (cg-RX-API-DMAC7.html)
CA (1) CA3229250A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023016516A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165077A1 (zh) * 2023-02-10 2024-08-15 信达生物制药(苏州)有限公司 一种包含抗vegfa和vegfc双特异性结合蛋白的药物制剂
WO2025250739A1 (en) * 2024-05-31 2025-12-04 Janssen Biotech, Inc. Chimeric antigen receptor with spacer domains derived from human igg

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403088B1 (en) * 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
CA3142945A1 (en) * 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Histidine-buffered formulations of vegf antagonist
EP2401296A1 (en) * 2009-02-24 2012-01-04 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
US8486397B2 (en) * 2009-12-11 2013-07-16 Genentech, Inc. Anti-VEGF-C antibodies and methods using same
CA2796205A1 (en) * 2010-04-15 2011-10-20 Vegenics Pty Limited Combination treatment with vegf-c antagonists
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
PH12014500220A1 (en) * 2011-07-27 2019-03-22 Glaxo Group Ltd Anti-vegf single variable domains fused to fc domains
KR102131370B1 (ko) * 2013-10-18 2020-07-08 삼성전자주식회사 Vegf-c에 특이적으로 결합하는 폴리펩타이드 및 그의 용도
CA2980189A1 (en) * 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
MY200973A (en) * 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
CN110305210B (zh) * 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
US20210130430A1 (en) * 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
CN108640994A (zh) * 2018-06-28 2018-10-12 浙江众意生物科技有限公司 一种vegf-c单克隆抗体及试剂盒
JP2022512657A (ja) * 2018-10-12 2022-02-07 トリカン・バイオテクノロジー・カンパニー・リミテッド 二機能性融合タンパク質およびその使用
EP3930754A4 (en) * 2019-02-27 2023-08-16 Zhejiang Nanomab Technology Center Co. Ltd. HIGH-THROUGHPUT SEQUENCE-BASED PROCEDURE FOR GENERATION OF CAMELID ANTIBODIES TO COVER WIDE EPITOPES WITH HIGH RESOLUTION
CN116003601B (zh) * 2019-12-05 2026-05-01 启愈生物技术(上海)有限公司 一种抗pd-l1纳米抗体及其用途
CN112961250B (zh) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 抗体融合蛋白及其应用

Similar Documents

Publication Publication Date Title
AU2022241522B2 (en) Bispecific antibody to a-syn/igf1r and use thereof
US9441040B2 (en) Antagonist antibodies and their fab fragments against GPVI and uses thereof
EP2050764A1 (en) Novel polyvalent bispecific antibody format and uses thereof
AU2011298281B2 (en) VEGF-binding molecules
US20220185875A1 (en) Bispecific antibody specifically bound to vegf and ang2
JP6608698B2 (ja) P2x7受容体アンタゴニスト及びアゴニスト
JP2021528973A5 (cg-RX-API-DMAC7.html)
JP2019533719A5 (cg-RX-API-DMAC7.html)
JP2024001073A5 (cg-RX-API-DMAC7.html)
AU2023202595B2 (en) BISPECIFIC ANTIBODY AGAINST a-SYN/IGF1R AND USE THEREOF
JP2023548529A5 (cg-RX-API-DMAC7.html)
CA3208455A1 (en) Novel anti-gremlin1 antibodies
JP2022521305A (ja) 抗pd-l1抗体及びその使用
WO2019080909A1 (en) TARGETING THERAPEUTIC ANTIBODY RANKL
CN113135995A (zh) 抗her3单克隆抗体及其应用
WO2025172587A1 (en) Binding constructs
JP2023539453A (ja) Bcmaと結合する単一可変ドメイン及び抗原結合分子
JP7808831B2 (ja) 抗cd26抗体とその応用
WO2025103451A1 (zh) Trgv9结合蛋白及其医药用途
JP2026510307A (ja) 抗cd3多重特異性抗体及びその使用方法
WO2026044000A1 (en) Multispecific antibodies and methods of use thereof
IL322877A (en) Multispecific antibodies against 6cldn and 3cd and methods of use
JP2023519620A (ja) Cd47に結合する抗原結合ポリペプチド及び用途